A Study to Learn About the Study Medicine (CIBINQO) in People With Atopic Dermatitis.

Last updated: May 12, 2025
Sponsor: Pfizer
Overall Status: Active - Recruiting

Phase

N/A

Condition

Skin Infections/disorders

Eczema (Atopic Dermatitis - Pediatric)

Atopic Dermatitis

Treatment

CIBINQO

Clinical Study ID

NCT05387980
B7451055
  • Ages > 12
  • All Genders

Study Summary

The purpose of this study is to learn about the safety and effectiveness (how well the study treatment works) of the study medicine (CIBINQO) for the potential treatment of atopic dermatitis in people under Japanese medical practice.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Participants receiving this Product for treatment of AD.

  2. Participants start receiving this Product (commercial product) for the first timeand no earlier than the contract date of this Study, or Participants who continuesto receive this drug after hospital transfer can be registered retrospectively.

Exclusion

Exclusion Criteria:

  1. Participants previously enrolled in this Study at the same site.

Study Design

Total Participants: 1200
Treatment Group(s): 1
Primary Treatment: CIBINQO
Phase:
Study Start date:
April 19, 2022
Estimated Completion Date:
August 02, 2028

Connect with a study center

  • Pfizer Local Country Office

    Tokyo,
    Japan

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.